ArticleEuropean journal of clinical investigation2026
Association between CMR-derived hepatic T1-time, tricuspid regurgitation and survival.
Article in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Myocardial remodeling in valvular heart disease: pathophysiology, multimodality imaging and treatment implications.Heart failure reviews · 2026Review
- CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis.European journal of clinical investigation · 2026Article
- Association between CMR-derived hepatic T1-time, tricuspid regurgitation and survival.European journal of clinical investigation · 2026Article
- T1 mapping in repaired tetralogy of Fallot: A marker of fibrosis or a mirror of hemodynamics?Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic ResonanceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac magnetic resonance (CMR) derived hepatic T1-time is associated with outcome. However, the interplay between tricuspid regurgitation (TR), which can cause congestive hepatopathy and liver T1-time is unclear.
methodsWe measured hepatic T1-time in CMR all-comers, who underwent echocardiography within 3 weeks of CMR. Kaplan-Meier estimates and Cox regression models were used to investigate the association between hepatic T1-time, TR severity and a composite endpoint of heart failure hospitalisation and all-cause death.
results1029 participants (67 ± 17 y/o, 44% female) had a mean hepatic T1-time of 605 ± 79 ms. Overall, 41% (417) presented with non/trace, 38% (391) with mild, 13% (135) with moderate and 8% (85) with severe/massive/torrential TR. Liver T1-time was significantly associated with TR severity (no/trace: 586 ± 72 ms; mild: 601 ± 74 ms; moderate: 634 ± 84 ms; severe/massive/torrential: 665 ± 83 ms; β = 25.4 ms, [95% CI:19.7-31.2, p < .001]). After adjustment for serum NT-proBNP and right ventricular function in a linear regression model, TR severity remained significantly associated with hepatic T1-time (p < .001). During follow-up (mean 53 ± 36 months) 326 (32%) events occurred. Hepatic T1-time (adj.HR 1.69 [95% CI: 1.49-1.92] per 100 ms increase, p < .001) and TR (adj.HR 1.66 [95% CI: 1.49-1.84], p < .001) were both associated with outcome. Even after adjustment for serum NT-proBNP, cardiac structure and function, age, sex and TR severity, hepatic T1-time remained significantly associated with event-free survival (adj.HR 1.42 [95% CI: 1.20-1.68] per 100 ms increase, p < .001).
conclusionTR exerts a notable influence on hepatic T1-time. Nevertheless, after adjustment for serum NTproBNP, cardiac function and TR severity, hepatic T1-time still independently predicts outcomes. This underscores the importance of hepatic T1-time both as a marker of TR and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.